Learn about this study
This Phase 1 study evaluates 89Zr-labelled olaratumab in Soft Tissue Sarcoma (STS). The trial aims to assess the safety, pharmacokinetics, and imaging characteristics of this novel radiotracer in patients with STS
Who can participate?
Participating in clinical research is a significant, personal decision. Before enrolling, the study team will fully explain the research and provide an Informed Consent Form that outlines possible benefits and risks. This is your chance to ask questions and consult with your doctor to determine if the study is right for you.
You may be able to participate if:
- You have been diagnosed with Soft Tissue Sarcoma
- You are eligible for PET/CT imaging
- You meet other specific inclusion criteria set by the study
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.